SGLT2 inhibitors in Patients Admitted for Acute Heart Failure: The Earlier the Betterdoi:10.1016/j.amjcard.2023.12.018Salvatore Carbone PhD, MSAntonio Abbate MD, PhDElsevier Inc.American Journal of Cardiology
The sodium–glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and dapagliflozin significantly reduce the risk of cardiovascular death or hospitalization for heart failure in patients with chronic heart failure with a reduced left ventricular ejection fraction (LVEF)9,10. Empagliflozin additionally sign...
SGLT2 InhibitorsRichard K. Cheng MD, MScDeidre M. Mooney MD, MPHChristopher V. Chien MDKevin S. Shah MDAmanda Vest MBBS, MPHJohn L. Jefferies MD, MPHJournal of the American College of Cardiology
SGLT2 Inhibitors to Treat Heart Failure Activity Do It Better: Raising the Bar in Heart Failure Care With Practical Strategies for Treatment With SGLT2 Inhibitors Released:March 14, 2025 Expiration:March 13, 2026 Javed Butler, MD, MPH, MBA ...
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multic...
[8] Packer M.(2020). Cardioprotective effects of Sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors, Circ Heart Fail, 13(9), e007197. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007197 [9] ...
This study aimed to quantify the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a therapeutic approach for heart failure. Methods A systematic literature review was conducted to collect pharmacokinetics (PK) and pharmacodyna...
SGLT2 inhibitors on heart failure events was not the primary endpoint of these trials; the phenotype of heart failure was not characterized; and the adequacy of background therapy was not established. Therefore, for many yea...
(SGLT2) inhibitors in HFpEF are encouraging. In addition to numerous experimental studies showing improvement in diastolic dysfunction parameters, the EMPEROR-Preserved study demonstrated for the first time clinically that therapy with the SGLT2 inhibitor empagliflozin significantly reduced hospitalization for...
To date, the use of SGLT2is in T1DM patients has yet to be approved by the FDA, who deems that the current benefits conferred by this therapy do not outweigh the risks that it carries.44,45 Metabolic benefits: SGLT2 inhibitors induce a state of fasting mimicry promoting a systemic ...